Diurnal, Clinigen sales and marketing update

Clinigen launched a patient access program in Europe to provide Diurnal’s cortisol deficiency candidates Infacort and Chronocort on a named-patient basis to patients who have no other treatment options.

Infacort is under EMA review to treat adrenal insufficiency, including congenital adrenal hyperplasia. Diurnal submitted the MAA to EMA in late 2016 for the dry granule formulation of hydrocortisone. Chronocort, a modified-release hydrocortisone tablet, is in a Phase III trial to treat adults with congenital adrenal hyperplasia. Diurnal expects to complete the trial in 2018...